RYBREVANT® is approved to treat advanced non–small cell lung cancer (NSCLC) with certain EGFR mutations

EGFR+ NSCLC with exon 20 insertion mutations
— 1st treatment —
Grey next arrow icon
EGFR+ NSCLC with exon 20 insertion mutations
— 2nd treatment —
Grey next arrow icon
Not sure which of the options above to select?
Ask your doctor and learn more about the types of lung cancer RYBREVANT® is approved to treat.
Learn about the optionsNext arrow icon
Videos
Real stories from people treated with RYBREVANT® infusions

Jimmy’s Story

Meet Jimmy, a patient treated with RYBREVANT® infusions. Hear about his experience and why sharing his story is important to him.

Doctor Discussion Guide

Tips and example questions for having a helpful discussion with your doctor.

Download the guideArrow pointing downward
RYBREVANT® doctor discussion guide thumbnailRYBREVANT® doctor discussion guide thumbnail

Savings & support

Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.

Rybrevant withMe logo with patientRybrevant withMe logo with patient
The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.
EGFR+ = mutated epidermal growth factor receptor